Form 4: Rocket Pharmaceuticals Officer Jonathan Schwartz Reports Stock Sales to Cover Tax Obligations

Jonathan Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Summary

• Jonathan Schwartz, an officer at Rocket Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The reported transactions involve the sale of common stock to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Sales occurred on May 17, 2024, August 16, 2024, November 21, 2024 and February 25, 2025.
• The sales prices ranged from $10.58 to $23.35 per share.
• After the reported transactions, Schwartz directly owns 237,638 shares of Rocket Pharmaceuticals common stock, inclusive of 80,318 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine stock sales for tax purposes, which is a normal part of executive compensation. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Sales to cover tax obligations are common and don't necessarily reflect a negative outlook on the company.

Stakeholder Impact

• The stock sales could have a minor, temporary impact on the stock price due to increased selling pressure.

Key Dates